Please join us as we speak to Dr. Daniel Pollyea from the University of Colorado School of Medicine. In this episode, Dr. Pollyea discusses the group of diseases that make up Myelodysplastic Syndromes (MDS) and how their variability leads to different treatments and prognoses, from active monitoring to chemotherapy and/or stem cell transplantation. He shares his excitement about new treatment advances and is looking forward to an era of innovative targeted treatments for MDS.
Podcast: Play in new window | Download
Subscribe: Google Podcasts | Spotify | Stitcher | Blubrry | JioSaavn | TuneIn | RSS | MoreCLICK HERE to participate in our episode survey.
Mentioned on this episode:
- Myelodysplastic Syndromes (MDS)
- Myelodysplastic Syndromes (MDS) Booklets
- Acute Myeloid Leukemia (AML)
- Stem Cell Transplant
- IPSS-R Scoring System
- IPSS-M Scoring System
- Clinical Trial Support Center
Additional LLS Support Resources:
- Information Specialists
- Financial support
- Free telephone/web patient programs
- Patti Robinson Kaufmann First Connection Program
- Free booklets
- LLS Public Policy & Advocacy
- Online chats
- Caregiver support
- Support groups
- Free Nutrition Consultations
- LLS Advocacy
- Survivorship Workbook
Support for this episode provided by Taiho Oncology.
Where are the clinical trials in Canada?
If you are a resident of Canada, we encourage you to contact The Leukemia & Lymphoma Society of Canada here: https://www.bloodcancers.ca/ or by dialing 1-833-222-4884. They should be able to help you with clinical trials available in Canada.
Very good information. Glad I listened.
I listened to this podcast and found it exceptionally helpful. I have MDS and had a BMT I am doing well. I appreciated hearing about the scoring. I am a NP so have increased interest personally and professionally.